This article from @KFFHealthNews is disinformation. It’s an insult to readers seeking honest reporting about NIH and misleads prospective patients who may need lifesaving care at @NIHClinicalCntr. Inpatient admissions at hospitals nationwide are in a long-term decline. But there

🤠 👉🏽 🗽 news: I will be joining @nyulangone on September 1, 2025 as Director of the GI Cancer Center & Associate Director of Translational Research at @Perlmutter_CC. I am excited to start the next chapter of the Maitra Lab in NYC & build a strong GI cancer research program.

🧵 Twenty-five years ago, it was common to hear complaints about a “drug lag”—the perception that Europeans routinely enjoyed medical advances years before their American counterparts. Through a generation of congressional actions, investments in expertise and hiring, and careful

How the @NIH dominates the world’s health research — in charts. Great comments by @MiriamMerad

Nearly 100 NIH study sections were canceled in the past month. Here is a list of the canceled meetings, compiled by Annika Barber at Rutgers Univ. As a result, the process of biomedical science funding has been halted in the United States. https://t.co/64wz2HUUYc

So what's happening with medical research in the US? This is the cumulative award count from the NIH for the year. Doesn't look so good. But it gets worse. 1/

Time to re-up this. Congrats to Larry T on a great career at NIH. A wonderful Fed.

If we want to thoughtfully reduce NIH indirect costs, we need to reduce the federal regulatory burden that causes universities to hire so many administrators to remain compliant.

Every year, ~90,000 teens and young adults receive a cancer diagnosis. Programs like those at @UNC_Lineberger—an NCI-Designated Comprehensive Cancer Center—help young people navigate treatment, enroll in trials, and get fertility counseling. Read more:

Novocure and its Tumor Treating Fields (TTF) Modality meets its Phase 3 trial primary endpoint of improving survival in local advanced #PancreaticCancer (LAPC). Caveats are several: - modest improvement in survival (one of those statistically significant but “is it meaningful”

A single-cell atlas of aging tissue demonstrates shared multi-omics of aging and cancer hallmarks https://t.co/DgBcpvYegc @NatureAging @jacksonlab @justsaysinmice @OlgaAnczukow

The rise of industry-sponsored cancer clinical trial enrollment from 2008 to 2022, now surpassing NIH-sponsored trials, highlights a shift in oncology research priorities. This trend may limit opportunities for addressing broader, patient-centered questions that are not

@PTarantinoMD @YAbdouMD @JCO_ASCO A link to the editorial by @YAbdouMD @nes047 @UNC_Lineberger https://t.co/dEn58AEHhF worth reading!

Out in JCO: the ratio of enrollment to Industry- vs Federally-sponsored trials doubled between 2008-2022. This led to an acceleration in drug development, but less trials exploring de-escalation or non-drug-related questions. Great editorial by @YAbdouMD. https://t.co/xEAndVHDrg

An important study by F. Eun-Hyung Lee's team shows that long lived plasma cells (the source of long-term circulating antibodies) fail to establish after mRNA vaccination (even combined with SARS-CoV-2 infection). 🧵 (1/) https://t.co/Z15xiyxCLS

I'm excited to announce that @NCICCHE Director Dr. Sanya Springfield will be an acting deputy director at @theNCI – in this new role, she'll be charged with broadening and strengthening our cancer health equity and inclusion efforts. #EndingCancerAsWeKnowIt for all.

I'm honored to present #SCLC updates at the 2nd annual Thomas C. Shea Clinical Cancer Symposium on Monday, September 23rd from the @UNC_Lineberger cancer center alongside Drs. @DrJaredWeiss @JulieBrahmer Mark Socinski @nes047 and others! In person @The_Umstead in Cary, NC!

Leading the @AmericanCancer Society + @ACSCAN is the honor of a lifetime. Over the last 3.5 years, we increased our impact and focused on improving the lives of cancer patients. I love this org! With ACS on strong footing and having accomplished what I came to achieve, today I

So sad to hear about the passing of Jeff Weber, a giant in the field of oncology. He was involved in the early days of cytokine and cell therapy and most recently led studies of personalized vaccines for melanoma patients. I originally worked with Jeff @theNCI over 30 years ago.

Vir Biotechnology announced today it's all but abandoning infectious disease research and pivoting to cancer. My story from May on how a grand, billion-dollar plan to build a company to create "a world without infectious disease" fell apart: https://t.co/jboFQYyWFQ